EGFR and neoplasm: Therefore, we designed a prospective clinical trial to reduce the tumour to a certain size and maintain a relatively stable state by using EGFR-tyrosine kinase inhibitors (EGFR-TKIs), which have an objective response rate (ORR) of more than 70%, to realize the reasonable timing of radiotherapy to reduce normal tissue toxicity and increase the radiation dose, and to provide a reference for further randomized controlled studies on the reasonable timing of radiotherapy.